SUBSCRIBE
SUBSCRIBE
News   Drug Development

Antibody Drug Cost-Effective For Allergic Asthma, University of Washington and Novartis Pharma AG Study

June 4, 2008 | 
1 min read

Reuters Health -- The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers and other mediations, according to a report in the journal Allergy.

Clinical research Postmarket research Europe
MORE ON THIS TOPIC
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Cancer
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
March 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
A white blood cell charging an ADC/
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky